echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sagimet, a partner of Songli, completes the first phase IIb clinical administration of patients with moderate to severe fibrosis NASH

    Sagimet, a partner of Songli, completes the first phase IIb clinical administration of patients with moderate to severe fibrosis NASH

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 16, Gerry Pharmaceuticals announced that its partner Sagimet Biosciences has completed the first patient administration of its non-alcoholic steatohepatitis (NASH) phase IIb clinical trial (FASCINATE-2)


    Primary efficacy endpoint:

    1.


    2.


    The US Food and Drug Administration (FDA) has approved the two primary efficacy endpoints of the NASH Phase IIb study


    In March 2021, Gan Lai Pharmaceutical Co.


    Gale has all indications for fatty acid synthase inhibitors (FASN) including ASC40 (TVB-2640) and all related compounds, including non-alcoholic steatohepatitis (NASH) and tumors developed, manufactured and commercialized in Greater China Exclusive rights


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.